Skip to main content
. 2011 Jun 1;17(6):PI15–PI23. doi: 10.12659/MSM.881792

Table 3.

Comparison of lab characteristics between treatment groups*.

L-carntine baseline (n) L-carnitine end (n) Total Δ (%) Placebo baseline (n) Placebo end (n) Total Δ (%) Contrast between groups (95% CI) P-value for contrast between groups
Serum Total-Carnitine (μmol/L) 48.8±18.8 (12) 82.7±22.0** (12) 33.9±21.1 (41) 47.1±17.4 (7) 55.7±21.4 (7) 8.6±10.1 (15.4) 25.3***(7.2 to 43) 0.009
Serum Free-Carnitine (μmol/L) 34.6±12.6 (12) 61.4±22.7 (12) 26.8±18.3 (43.6) 35.7±13.0 (7) 35.7±16.1 (7) 0.0±13.6 (0.0) 26.8 (9.9 to 44) 0.004
Whole Blood WBC (×103/μL) 6.8±2.4 (12) 7.0±2.2 (12) 0.2±1.6 (2.9) 7.5±1.7 (8) 7.7±4.7 (8) 0.2±5.7 (2.6) 0 (−4.3 to 4.3) 0.99
Whole Blood RBC (×103/μL) 4.6±0.30 (12) 4.7±0.28 (12) 0.1±0.25 (2.1) 4.6±0.25 (8) 4.5±0.30 (8) −0.01±0.20 (−2.2) 0.11 (−0.11 to 0.33) 0.31
Whole Blood Platelet Count (×103/μL) 297±87.8 (12) 272±103 (12) −25±76 (−8.4) 324±61.3 (8) 283±50.8 (8) −40±51.3 (−12.6) 15 (−50 to 80) 0.63
Serum Creatinine (mg/dL) 0.43±0.10 (12) 0.49±0.16 (12) 0.06±0.19 (12.2) 0.43±0.07 (8) 0.44±0.06 (8) 0.01±0.06 (2.3) 0.05 (−0.07 to 0.17) 0.41
Serum BUN (mg/dL) 10.8±2.9 (12) 12.3±3.6 (12) 1.5±3.1 (12.2) 12.5±2.7 (8) 15.3±3.2 (8) 2.8±4.0 (18.3) −1.3 (−4.6 to 2.0) 0.42
Serum Alkaline Phophatase (IU/L) 209±52.2 (12) 235±55.7 (12) 26±55.7 (11.1) 227±59.2 (8) 241±50.8 (8) 14±33.9 (5.8) 12 (−34 to 58) 0.60
Serum AST/SGOT (IU/L) 30.6±5.3 (12) 30.8±4.8 (12) 0.20±4.3 (0.65) 32.9±6.1 (8) 31.6±4.0 (8) −1.3±4.8 (−3.9) 1.5 (−2.8 to 5.8) 0.48
Serum ALT/SGPT (IU/L) 16.4±3.8 (12) 18.0±3.6 (12) 1.6±2.6 (8.9) 15.9±3.9 (8) 16.5±4.4 (8) 0.6±3.8 (3.6) 1.0 (−2.0 to 4.0) 0.49
Serum Glucose (mg/dL) 86.3±6.1 (12) 83.5±8.1 (12) −2.8±9.5 (−3.2) 87.6±8.2 (8) 78.9±14.7 (8) −8.7±11.6 (−9.9) 5.9 (−4.04 to 16) 0.23

ALT/SGPT – alanine aminotransferase; AST/SGOT – aspartate aminotransferase; BUN – blood urine nitrogen; CI – confidence interval; RBC – red blood cell count; WBC – white blood cell count;

**

mean ±SD;

***

t-test statistic.